Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission
Sign Up to like & getrecommendations! Published in 2022 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1010698
Abstract: Baloxavir marboxil (BXM) is approved for treating uncomplicated influenza. The active metabolite baloxavir acid (BXA) inhibits cap-dependent endonuclease activity of the influenza virus polymerase acidic protein (PA), which is necessary for viral transcription. Treatment-emergent E23G… read more here.
Keywords: e23g substitutions; transmission; influenza virus; bxa ... See more keywords